Allievex Corporation
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE (NCT05492799) | Allievex Corporation | 2022-12-02 |
| A Treatment Extension Study of Mucopolysaccharidosis Type IIIB (NCT03784287) | Allievex Corporation | 2018-02-19 |
| A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB) (NCT03227042) | Allievex Corporation | 2017-11-16 |
| A Treatment Study of Mucopolysaccharidosis Type IIIB (NCT02754076) | Allievex Corporation | 2016-04-01 |
| A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB) (NCT02493998) | Allievex Corporation | 2015-11-01 |
Track Allievex Corporation automatically
Every clearance here is in the API, with alerts when new ones post.